title: Intended management of children with acute idiopathic thrombocytopenic purpura: a national survey.
abstract: OBJECTIVE
  In Australia acute idiopathic thrombocytopenic purpura (ITP) is mainly treated by paediatricians (either general paediatricians or paediatric haematologists/oncologists). A survey was conducted to gauge the current practice of treating children with acute ITP in Australia.
  
  
  METHODS
  All practising Australian paediatricians registered by the Royal Australasian College of Physicians were surveyed regarding their intended management of children with acute ITP. The questionnaire, adapted from a study of paediatric haematologists/oncologists in North America, presented four clinical scenarios of children with acute ITP with a platelet count of 3000 x 10(9)/L, with and without mucosal bleeding (wet and dry purpura, respectively). Questionnaires were returned by mail or filled in online at a dedicated webpage.
  
  
  RESULTS
  Five hundred and sixty-three of 1097 (51%) paediatricians responded to the survey. Data from 140 who had treated at least one child with ITP in the previous 12 months were analysed. Respondents indicated that children with acute ITP are usually or always hospitalised (58-92%) and that 48% would be given active treatment, even with dry purpura. Various regimens of i.v. immunoglobulin or corticosteroids are used when treatment is administered. In comparing Australian and North American management of acute ITP there were many similarities, although Australian paediatricians were less likely to arrange a bone marrow aspirate if corticosteroids were prescribed.
  
  
  CONCLUSIONS
  There is great variation in the intended management of children with acute ITP in Australia. Previously published management recommendations regarding investigation and treatment have had little impact on intended practice. Prospective studies are required to evaluate hypotheses so as to produce evidence-based recommendations for treatment of patients with acute ITP.
authors.affiliation: Royal Children's Hospital, Melbourne, Victoria, Australia. michael.marks@rch.org.au
authors.forename: M K
authors.initials: MK
authors.lastname: Marks
authors.forename: B
authors.initials: B
authors.lastname: Vadamalayan
authors.forename: H
authors.initials: H
authors.lastname: Ekert
authors.forename: M J
authors.initials: MJ
authors.lastname: South
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D001315:Australia; D002675:Child, Preschool; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007223:Infant; D009656:North America; D010372:Pediatrics / Q000706:statistics & numerical data; D010818:Practice Patterns, Physicians'; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011795:Surveys and Questionnaires
chemical_list: D000305:Adrenal Cortex Hormones; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D011239:Prednisolone